Caroline Seymour

Patients with ESCC treated in 2 tislelizumab-based arms experienced higher composite complete response rates compared to chemoradiotherapy alone.

BNT111 combined with cemiplimab showed promising efficacy in treating PD-(L) PD-L1-relapsed/refractory melanoma, achieving an 18.1% objective response rate.

Meta: Safety outcomes, including the treatment-related AEs and AEs leading to treatment discontinuation, were consistent with or without lenvatinib in ESCC.

Daratumumab, lenalidomide, ixazomib, and dexamethasone yielded PFS/OS outcomes in transplant-ineligible, newly diagnosed myeloma.

Zidesamtinib was well tolerated in patients who received prior ROS1 TKI therapy with advanced NSCLC, and dose discontinuation/reduction rates were low.

Efficacy and biomarker analyses from CheckMate-77T support perioperative nivolumab as an effective option in resectable NSCLC.

Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Vepdegestrant shows significant clinical activity and a favorable safety profile in ESR1-mutant HER2-negative, ER-positive metastatic breast cancer vs fulvestrant.

Final OS data from INAVO120 demonstrate, for the first time, a significant OS improvement with a PI3K-targeted agent in this breast cancer population.

A phase 2 study found a complete clinical response of 82% with neoadjuvant dostarlimab in dMMR solid tumors.

Results from the OVARIO trial found HRQOL maintained with niraparib/bevacizumab maintenance in patients with advanced ovarian cancer.

Cadonilimab plus lenvatinib appeared to have a manageable safety profile in a phase 2 trial.

Phase 1/2 SYLT-023 trial evaluated the efficacy and safety of tislelizumab plus chemotherapy in patients with advanced, HER2-negative, mismatch repair–proficient gastric/GEJ cancer.

For patients with hormone receptor-positive and HER2-low breast cancer, T-DXd elicited higher levels of PFS despite time to progression and disease burden.

Phase 3 data support tafasitamab plus lenalidomide/rituximab as a potential new standard of care in patients with relapsed/refractory follicular lymphoma.

Regardless of high-risk features, brexucabtagene autoleucel demonstrated positive and durable responses in BTK-naive MCL.

For patients with relapsed/refractory large B-cell lymphoma, PFS and OS data from CD-19-directed, 4-1BB CAR T-cell Liso-cel therapy were consistent with prior results.

Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors.

Final analysis data from LITESPARK-005 support belzutifan as a treatment for patients with previously treated advanced clear cell RCC.

Data from the HARMONi-2 trial support the potential superiority of frontline ivonescimab vs pembrolizumab in non–small cell lung cancer.

No patients with dMMR rectal cancer enrolled on a phase 2 study required subsequent chemotherapy or radiation following treatment with dostarlimab.

The addition of liver transplant to chemotherapy in those with colorectal cancer and liver metastases boosted overall survival.

Phase 1b data support the promising therapeutic benefit of vepdegestrant/palbociclib in ER-positive breast cancer regardless of ESR1 mutation status.

The phase 2/3 NRG-GY005 trial assessing olaparib plus dediranib did not improve survival vs standard of care in ovarian cancer.

Benefits with enfortumab vedotin plus pembrolizumab in prespecified patient subgroups with urothelial carcinoma in the EV-302 trial appear to be consistent with outcomes in the overall study population.

Durvalumab plus bevacizumab and TACE may be a new standard of care in unresectable hepatocellular carcinoma eligible for embolization, according to Riccardo Lencioni, MD.

DZD8586 results in favorable safety with limited grade 3 or greater treatment-emergent adverse effects in those with B-cell non-Hodgkin lymphoma, according to data from 2 ongoing phase 1 trials.

Data from the phase 3 PERSEUS trial supports D-VRd followed by DR maintenance as a new standard of care in patients with newly diagnosed, transplant-eligible multiple myeloma.

When used as a minimal residual disease (MRD)–guided treatment approach, ibrutinib (Imbruvica) combined with venetoclax (Venclexta) improved progression-free and overall survival (OS) compared with fludarabine, cyclophosphamide, and rituximab (Rituxan; FCR) in patients with treatment-naive chronic lymphocytic leukemia (CLL), as observed in the phase 3 FLAIR trial.

Older patients with hematological malignancies who received Orca-T therapy plus myeloablative chemotherapy have similar relapse-free survival rates compared with younger patients.